Future experiments will also include co-culturing cytotoxic CD8+ T-lymphocytes as well as Natural Killer (NK) cells with pancreatic tumor cells under monotherapy and combination therapy conditions to analyze whether the drugs are capable of sensitizing tumor cells to immune killing. This evidence concerns the gene CD8A and pancreatic neoplasm.